BPC-157 is the supportive layer
@Amgen thinks so, releases @Nature phase 1 study of AMG 133 (maridebart cafraglutide) a combination of GIPR antagonist monoclonal anti- body and two GLP-1 agonist peptides Safe, tolerable with dose-dependent weight loss maintained to 150 days go.nature.com/3HUHBjB Join the conversation
These findings further support its safety and efficacy in the treatment of EDC (Rangarajan et al., 2022)
Trust Deficit: When Medicine Becomes Marketing If the early promise of GLP-1 telehealth was access, its emerging challenge is accountability
You can also obtain both through dietary sources, but supplements often provide higher doses
Nevertheless, the study fails to clarify differences in serum PCS levels among PBC patients at different disease stages, uses non-human primary Kupffer cells in vitro , and does not evaluate the safety threshold for clinical PCS supplementation, which limits its therapeutic translation